Core Insights - Medtronic plc (NYSE:MDT) is recognized as a strong slow growth stock, with Truist Securities raising its price target to $110 from $103 while maintaining a Hold rating [1] - The company's fiscal second-quarter results showed significant revenue growth driven by its Pulsed Field Ablation (PFA) technology [1] Financial Performance - Medtronic's cardiac ablation solutions (CAS) division experienced a 71% year-over-year organic sales increase in the fiscal second quarter, attributed to the PFA technology [2] - In the last two fiscal quarters, CAS sales rose approximately 50% and 30%, indicating steady growth as PFA adoption continues [2] Strategic Investments - Truist noted an operating margin miss and a slight increase in earnings per share expectations despite revenue exceeding estimates, due to Medtronic's increased reinvestment ahead of major product launches [3] - This strategic investment is seen as limiting potential upside growth and profit acceleration [3] Company Overview - Medtronic is a leading name in medical technology, focusing on device-based therapeutics, with significant advancements in spine and minimally invasive treatments [4] - The company is recognized as a leader in robotic-assisted surgery technology [4]